Riskpilot← Back to searchSign inGet full accessUltupharma AB
ABActiveOrg 5590282892Södra Rudbecksgatan 13Research and experimental development on natural sciences and engineering · NACE 7210Est. 20150 employees
Revenue 2024
SEK 0
EBITDA margin
—
-80% vs 2023
Equity ratio
58.5%
Financial strength
Net profit 2024
SEK -642K
-80% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -642K | -80% |
| Net profit | SEK -642K | -80% |
| Total assets | SEK 200K | -4% |
| Equity | SEK 117K | -26% |
| Employees | 0 | — |
Legal name
Ultupharma AB
Org number
5590282892
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29 september 2015
Share capital
SEK 80 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska direkt eller indirekt, bedriva verksamhet inriktad på forskning, utveckling, tillverkning och försäljning av läkemedel och därmed förenlig verksamhet.
Address
Södra Rudbecksgatan 13
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 300 | 50 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | −643 | −7 711 | −8 243 | −6 430 | −3 706 | −2 654 | −525 | −356 | −642 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −643 | −7 711 | −8 243 | −6 430 | −3 706 | −2 654 | −525 | −356 | −642 |
| Net financials | — | — | — | — | — | −1 | — | — | — |
| Profit before tax | −643 | −7 711 | −8 243 | −6 430 | −3 706 | −2 655 | −525 | −356 | −642 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −643 | −7 711 | −8 243 | −6 430 | −3 706 | −2 655 | −525 | −356 | −642 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 112 | 7 504 | 13 008 | 6 550 | 3 407 | 783 | 197 | 208 | 200 |
| Equity | 28 | 7 317 | 12 589 | 6 159 | 2 453 | 590 | 165 | 159 | 117 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 84 | 187 | 419 | 392 | 954 | 192 | 31 | 49 | 83 |
| Total debt | 84 | 187 | 419 | 392 | 954 | 192 | 31 | 49 | 83 |
EBITDA margin
-64200000.0%
This company
15.8%
Market median
-406329214% vs market
20162024
Equity ratio
58.5%
This company
38.2%
Market median
+53% vs market
20162024
Return on equity
-548.7%
This company
18.4%
Market median
-3082% vs market
20162024
Net profit margin
-64200000.0%
This company
8.1%
Market median
-792592693% vs market
20162024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162024
Debt / equity
0.71×
This company
0.62×
Market median
+15% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KJ Chief Auditor | Chief Auditor | 2020 | — | — |
BF Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ultupharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Johan Herman Mattsson | Chief Auditor | 0 companies |
| Bo Fredrik Öberg | Chief Executive Officer | 0 companies |
| Anders Erik Broberg | Board of Directors | 0 companies |
| Malin Terése Åkesson | Board of Directors | 0 companies |
| Nina Lindblom | Board of Directors | 0 companies |
| Lars Johan Schnürer | Chairman | 0 companies |
| Johan Giesecke | Board of Directors | 0 companies |